JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 ...

Spyre Therapeutics (SYRE) stock analysis: de-risked pipeline, cash runway to H2 2028, and 2026–2027 Phase 2 catalysts in ...

FP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide continuous suppression of gonadotropin secretion ...

HOUSTON, Dec. 18, 2025 /PRNewswire/ -- CAZ Investments ("CAZ"), one of the world's 120 largest private equity allocators with $10.3 billion in assets under management and a global network of over ...

Business development companies are set for their worst year relative to the SandP 500 since 2020, leading some investors to question their future in the $1.7 trillion private credit market.

Polymatech Electronics Limited today announced a landmark milestone in India’s medical device sector with the successful registration and commencement of domestic manufacturing of its ...

The study identifies AI data centers as a fundamentally distinct category of electricity consumer. Traditional data centers ...

Detailed price information for Churchill Resources Inc (CRI-X) from The Globe and Mail including charting and trades.

Preliminary but promising.Those three words emerged as a recurring theme in conversations about several abstracts presented at this year’s ASH Annual Meeting and Exposition that examined the effects ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

Instead of following any kind of rigid programme, we did one or two classes per week for 10 weeks – either a strength-based ...